ReviewFrontiers in pharmacology2025
The pathogenesis of diabetic kidney disease and the therapeutic potential of bioactive substances.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of Curcumin/Turmeric Supplementation on Kidney Function in Individuals With Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Endocrinology, diabetes & metabolism · 2026Pooled it
- Anti-inflammatory and antioxidant effects of salidroside in diabetic nephropathy: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
- Urinary Extracellular Vesicle-Derived miRNAs as Regulators and Biomarkers in Diabetic Kidney Disease.International journal of molecular sciences · 2026Review
- Mogroside V Alleviates Renal Injury in Diabetic Mice via Regulation of theInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD), one of the common complications of diabetes, is a major contributor to chronic kidney disease (CKD) worldwide. Due to its high incidence and disability rates, DKD poses a serious threat to human health and represents a significant public health burden. Although current treatments, such as angiotensin-converting enzyme (ACE) inhibitors, are available, they remain limited in pharmacological effects. Medicinal plants are valuable resources for drug development, and their bioactive compounds have attracted considerable attention for their therapeutic potential in DKD. In this review, we systematically searched major scientific databases (e.g., PubMed) for studies published within key timeframes relevant to each topic. Keywords such as "DKD and oxidative stress" and "diabetic nephropathy and bioactive substances" were used to identify high-quality original research and review articles closely aligned with the theme of this work. Based on the selected literature, we summarize the pathogenic mechanisms of DKD and elucidate the therapeutic effects and mechanisms of bioactive substances-including polyphenols, peptides, polysaccharides, and flavonoids-in its treatment. A comparative analysis is also presented to provide a foundation for future pharmacological research on DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.